APA (7th ed.) Citation

CS, S., P, C., K, J., R, W., G, R., F, D., . . . S, G. (2019). Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. Journal for immunotherapy of cancer, 7(1), 314. https://doi.org/10.1186/s40425-019-0791-x

Chicago Style (17th ed.) Citation

CS, Shemesh, et al. "Population Pharmacokinetics, Exposure-safety, and Immunogenicity of Atezolizumab in Pediatric and Young Adult Patients with Cancer." Journal for Immunotherapy of Cancer 7, no. 1 (2019): 314. https://doi.org/10.1186/s40425-019-0791-x.

MLA (9th ed.) Citation

CS, Shemesh, et al. "Population Pharmacokinetics, Exposure-safety, and Immunogenicity of Atezolizumab in Pediatric and Young Adult Patients with Cancer." Journal for Immunotherapy of Cancer, vol. 7, no. 1, 2019, p. 314, https://doi.org/10.1186/s40425-019-0791-x.